Post-approval safety studies have traditionally been cumbersome and expensive, and safety study sites are likely to mirror those used in clinical trials, leading organizations to potentially miss safety signals in populations beyond those that typically participate at trial sites. Here we speak with Stefan C. Weiss, MD, Managing Director, Dermatology at OM1 about a transformation in the way we conduct safety studies — relying on EMR patient data overlain with technology to create a more accurate and equitable view of post-market safety.

Ver todos los episodios